ACXP — Acurx Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1736243 ·
Last close
$1.40
Market Cap
$6.02M
52W High
$2.06
52W Low
$1.31
ADV30
165,285
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,715,990 | -1,680,982 | 9,539,952 | 9,254,813 | 2,526,809 |
| Dec 2025 | 0 | — | -1,617,116 | -1,578,276 | 7,689,535 | 7,556,100 | 2,420,943 |
| Sep 2025 | 0 | — | -2,028,701 | -1,992,790 | 6,105,211 | 5,906,802 | 2,468,175 |
| Jun 2025 | 0 | — | -2,269,683 | -2,246,279 | 6,157,858 | 6,064,128 | 2,591,527 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,143,816
Investing CF
—
Financing CF
$10,754,742
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-5.89
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-76,969,476
Inventory
—
Receivables
$56,313
ST Investments
—
EBIT TTM
$-7,631,490
Pretax Income TTM
$-7,498,327
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -8,091,983 | -7,966,538 | 7,689,535 | 2,420,943 | — | -6,787,782 |
| Dec 2024 | 0 | -14,123,227 | -14,103,103 | 3,857,963 | 3,242,842 | — | -10,383,431 |
| Dec 2023 | 0 | -14,577,768 | -14,577,768 | 7,709,123 | 3,042,438 | — | -9,800,885 |
| Dec 2022 | 0 | -12,092,776 | -12,092,776 | 9,376,706 | 2,061,685 | — | -7,542,290 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.75
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PCSA | Processa Pharmaceuticals, Inc. | $6.06M | $2.17 | — |
| NCNA | NuCana plc | $6.12M | $1.47 | — |
| ERNA | Ernexa Therapeutics Inc. | $5.87M | $5.03 | — |
| PMHS | Polomar Health Services, Inc. | $6.19M | $0.22 | — |
| RVPH | REVIVA PHARMACEUTICALS HOLDINGS, INC. | $6.27M | $0.48 | — |
News headlines (Yahoo Finance, 1h cache)
Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...
2026-08-21 01:02 · Yahoo
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
2026-08-14 11:01 · Yahoo
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
2026-08-12 12:01 · Yahoo
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
2026-07-14 12:00 · Yahoo
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
2026-07-08 12:00 · Yahoo
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Developmen
2026-06-16 12:00 · Yahoo
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why
2026-06-08 16:00 · Yahoo
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
2026-05-12 11:01 · Yahoo
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
2026-04-29 12:00 · Yahoo
Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit
2026-04-27 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.